Display of the human mucinome with defined O-glycans by gene engineered cells
Nature Communications, ISSN: 2041-1723, Vol: 12, Issue: 1, Page: 4070
2021
- 78Citations
- 168Captures
- 4Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations78
- Citation Indexes77
- 77
- CrossRef36
- Patent Family Citations1
- Patent Families1
- Captures168
- Readers168
- 168
- Mentions4
- News Mentions3
- News3
- Blog Mentions1
- Blog1
Most Recent Blog
MUCUS et MUCINES : Les ingrédients des médicaments du futur ?
Le mucus et ses mucines pourraient devenir la base de médicaments du futur. Pourquoi ? Parce que les mucines, de grandes protéines glycosylées présentes dans le mucus « attirent » les bactéries -et certains virus aussi- via leurs structures en sucre. Cette équipe de biologistes de l’Université de Copenhague qui publie dans la revue Nature Communications, suggère de produire et d’utiliser le mucus
Most Recent News
Mucus and Mucins may Become the Medicine of the Future
Copenhagen, Denmark — Many people instinctively associate mucus with something disgusting, but in fact, it has incredibly many valuable functions for our health. It keeps
Article Description
Mucins are a large family of heavily O-glycosylated proteins that cover all mucosal surfaces and constitute the major macromolecules in most body fluids. Mucins are primarily defined by their variable tandem repeat (TR) domains that are densely decorated with different O-glycan structures in distinct patterns, and these arguably convey much of the informational content of mucins. Here, we develop a cell-based platform for the display and production of human TR O-glycodomains (~200 amino acids) with tunable structures and patterns of O-glycans using membrane-bound and secreted reporters expressed in glycoengineered HEK293 cells. Availability of defined mucin TR O-glycodomains advances experimental studies into the versatile role of mucins at the interface with pathogenic microorganisms and the microbiome, and sparks new strategies for molecular dissection of specific roles of adhesins, glycoside hydrolases, glycopeptidases, viruses and other interactions with mucin TRs as highlighted by examples.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know